Share Name Share Symbol Market Type Share ISIN Share Description
Dawmed Systems LSE:DSY London Ordinary Share GB0030032881 ORD 5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 5.00p 0.00p 0.00p - - - 0.00 05:00:10
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services - - - - 1.03

Dawmed Systems Share Discussion Threads

Showing 226 to 243 of 250 messages
Chat Pages: 10  9  8  7  6  5  4  3  2  1
DateSubjectAuthorDiscuss
27/8/2015
21:51
Tracked through.
alex turner phd
22/7/2009
13:54
Wow - some move today. Somebody somewhere knows something.
jambo172
06/7/2009
14:20
MC now circa £550k. Cash £800k + Bank Facilities to invest ??
double6
06/7/2009
11:50
"Following the sale of DIL, DMS will become an investing company for AIM Rules purposes and its proposed investing policy will require approval by shareholders of DMS. Following completion of the Sale the Continuing Directors, being Kevin Gilmore, Gordon Arbib and Nicholas Trigg, propose that, instead of winding up the Company, the Company's share capital should remain admitted to trading on AIM and that the Company's New Investing Policy should be based predominantly upon the acquisition for and development of and/or investment in commercial property, commercial property agency and the acquisition of land for and development of high end residential property, together with potential corporate acquisitions, the latter mainly in the property sector." So from washer disinfectors to property company, no wonder the market has reacted as such to this! Best of luck with this move, the market is at a bottom, but I just can't see how a management company which had been higly focussed and qualified in a niche sector can switch and sart making decisions about property acquistion. I think DIL will be wound up in 12-24 months time afetr all the cash has been spent. Wonder how barclays with their holding feel about this one or if they have advised this move.
freestyle
05/7/2009
20:07
Sale of Operating Subsidiary (Dawmed Systems) TIDMDSY RNS Number : 1325V DawMed Systems PLC 03 July 2009 ? For Immediate Release 3 July 2009 DawMed Systems plc ("Company") Sale of Operating Subsidiary DawMed Systems plc ("DMS") announces that it has today signed a conditional agreement with Wassenburg & Co B.V. ("Wassenburg") for the sale of all the issued share capital in DawMed International Limited ("DIL"), DMS' sole operating subsidiary. The consideration for the sale is the sum of GBP950,000 in cash (to be paid on completion). Completion accounts will be drawn up as at 1 July 2009 and there will be an adjustment to the consideration on the basis of DIL's net assets being more or less than GBP75,000. DMS and Wassenburg will each share 50% of any such shortfall in or excess of net assets. Whilst the Directors believe that the Second Interim Results were relatively satisfactory and pointed to an anticipated continuation of growth up to the period ended 31 March 2009, the Board considers that there are fundamental reasons why the present business does not provide a long-term basis for the Company's future viability as an independent entity. The Company is largely reliant upon its distribution agreement with Wassenburg for its imported equipment and the vagaries of the Sterling/Euro currency exchange rates mean that any profit margin on sales can be easily wiped out by a small change in the exchange rates. The sale of DIL is subject, inter alia, to the consent of shareholders of DMS. Conditional upon the completion of the sale of DIL, John Crispin and Mark Adamson will cease to be directors of DMS, but will continue as directors of DIL. The Directors of DMS believe that, having explored other sales opportunities, the sale of DIL at the above price is the best return that can be expected. Following the sale, the Company will be an investing company with net cash resources of approximately GBP800,000 being the proceeds of the sale, which, together with available bank finance will be utilised for the proposed investing policy. In the 18 months to 31 March 2009, DIL reported an audited loss on ordinary activities before taxation of GBP473,410 (year ended 30 September 2007: GBP571,508) on a turnover of GBP12,209,849 (year ended 30 September 2007: GBP4,976,158). During this period, DIL issued 2,184,500 new shares at par to the Company to strengthen its balance sheet. At 31 March 2009, DIL had net assets of GBP83,870 (30 September 2007 net liabilities: GBP1,627,220). A more detailed explanation of the trading performance of DIL will be provided in the circular to shareholders referred to below. Following the sale of DIL, DMS will become an investing company for AIM Rules purposes and its proposed investing policy will require approval by shareholders of DMS. Following completion of the Sale the Continuing Directors, being Kevin Gilmore, Gordon Arbib and Nicholas Trigg, propose that, instead of winding up the Company, the Company's share capital should remain admitted to trading on AIM and that the Company's New Investing Policy should be based predominantly upon the acquisition for and development of and/or investment in commercial property, commercial property agency and the acquisition of land for and development of high end residential property, together with potential corporate acquisitions, the latter mainly in the property sector. A circular will be despatched to DMS shareholders as soon as reasonably practicable, which will provide further details of the sale and the reasons for the sale, and convening two general meetings, the first to approve the sale of DIL and the DMS' proposed investing policies under the AIM Rules (which will be ordinary resolutions) and the second to approve the change of name of DMS (which will be a special resolution). 3 July 2009 Enquiries: Kevin Gilmore Chairman DawMed Systems plc01608 682244 Roland Cornish Chairman Beaumont Cornish Limited 020 7628 3396 This information is provided by RNS The company news service from the London Stock Exchange END DISBLGDRGBGGGCX
gelp
19/6/2009
11:20
Now that the talks are over it's back to the doldrums
freestyle
04/6/2009
09:57
Any more thoughts? 2nd on top lists so far and seems more trades than usual.
gelp
22/5/2009
11:07
Gelp, Thanks for your thoughts, done a little trawling on analyists side and have come up blank. Suppose I'll have to wait and see.
freestyle
22/5/2009
07:05
sp rose in march cos of RNS loss to profits etc great imp share price up.the deals since then are insignificant surely.the share price is reacting to the announcements. who are likely to be interested/benfit from a deal with long established op in the decom/medical field.. Synergy , tristel, ?? must be others as well + international suppliers. Freestyle says mcap but i think means value. assetts inc good will + multiple of fwd earns - interesting guess work. At present mc is sitting duck surely.Listing costs alone would go if taken by other listed or larger co.
gelp
21/5/2009
23:14
where do you get the mrk cap of 5-6mln from
frankiestheone
21/5/2009
19:09
down today, like the build up to the announcement of the approach I think someone might know if the approach has been stymid hence the movement. pure speculation but that my thoughts. then again never say never until the rotund lady sings.
freestyle
20/5/2009
14:43
OK chaps, Pure speculation thread. I've held these since first listing be intertested to hear of your thoughts for price to be paid for the company and how it will be paid should the approach turn into a takeover. My thoughts are: Market cap of the company £5-6M, paid for cash.approx 25-30p per share Be interesting to see how much the intangibles will be costed at, patents, brands etc.
freestyle
18/5/2009
09:05
Hope they don't give it away at a cheap price. Turnover >£7m, profitable and good order book. Please be greedy on price!
jambo172
16/5/2009
12:30
Takeover approach! Announced after market close last night. Now if its over 22p a share I might break even ;)
devbod
28/4/2009
21:53
Whilst I doubt that the swine flu outbreak will have a direct effect on DAWMED, I expect that it will act as a reminder to the various hospital authorities and local clinics on the importance of sterilisation of equipment. I suppose one of the advantages of the clinic is it's small size and portability. Ideal for small surgeries.
freestyle
28/2/2009
09:14
Agree with you there, Gelp. I notice that Dawmed, like many other tiny AIM companies, is running out of Market Makers. A year ago they had 4 market makers covering the stock but today Winterfloods is the only one. This does lead to a wider spread and tends to increase volatility with the price moving a lot on low volume. MJ
mjcrockett
28/2/2009
09:08
Not hard to see why the the share is being rerated - the interim report clearly showed optimism & recovery improgress & profit forcast - but no body either read it or believed it as was so long coming! I think we misread the accounting date change as a negative and assumed 12 month figures would be depressed - looks like there was no ulterior motive at all. The price just continually drifted down & accellerated due to the market conditions. In spite of the banks efforts to drag every one else down life does go on & I guess that a combination of long experience and close supplier support and determination plus perhaps a liitle luck (the harder you work the luckier you get..!) have enable a genuine improvement on all fronts. The lows in price were never really available in any numbers (the tripling has to be viewed in context) & i guess those in similar markets will be viewing the lowly valuation with interest as will the directors if the price does not seriously respond to the better news. Well done Directors for keeping the news really quiet - no leakages!
gelp
27/2/2009
11:24
no chatter here.. price trebled.
powwow
Chat Pages: 10  9  8  7  6  5  4  3  2  1
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:34 V: D:20161206 14:08:21